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Abstract The late side-effects of the local therapy of early
breast cancer depend on many patient- and therapy-related
parameters.We aimed at investigating the factors that influence
the cosmetic and functional outcomes among our breast cancer
patients after breast-conserving surgery and conformal radio-
therapy, with or without adjuvant systemic therapy. A study
was made of the association of the cosmetic outcome after a
median follow-up time of 2.4 years and the clinical data on 198
patients extracted from a prospectively compiled database.
Breast tenderness occurred more frequently among patients
≤50 years old (p<0.05). Long-term side effects were related to
radiotherapy-related factors the most, while no effect of the
systemic therapy could be detected. The risk of hyperpig-
mentation, breast edema and breast fibrosis increased by
18%, 23% and 7%, respectively for every 100 cm3 increase
in the irradiated breast volume, while that of breast edema
and breast fibrosis increased by 21% and 12%, respectively
for every 10 cm3 increase in the boost volume. Patients who
received a photon boost were significantly more likely
to develop breast edema and fibrosis than those who
received electrons (p<0.005). Dose inhomogeneity was
related to the volume of the irradiated breast (p=0.037).
Dyspigmentation developed more often among patients
older than 50 years, while smoking favoured both
dyspigmentation and teleangiectasia. Breast edema was
related to dyspigmentation (p=0.003), fibrosis (p<0.001)
and breast asymmetry (p=0.032), whereas none of these
abnormalities were associated with teleangiectasia. Body
image changes were more frequent at a younger age (p<
0.005), while the need to change clothing habits occurred
more often at an older age (p<0.05). Radiotherapy-related
parameters appear to exert the greatest effect on the
overall cosmetic outcome after breast-conserving surgery
and postoperative radiotherapy.
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Introduction
Breast-conserving surgery, usually followed by whole-breast
irradiation, is the most widely used surgical option for early
breast cancer [1–5]. Postoperative irradiation and adjuvant
systemic therapy improve both local control and survival [2,
6]. The cosmetic and the functional outcome after postoper-
ative breast radiotherapy depend on numerous patient- and
therapy-related factors. The age, the menopausal status, the
weight and the general health status of the patient, the stage
of the tumor and the surgical intervention clearly influence
the results [7]. The radiogenic changes of the breast, such as
dyspigmentation, teleangiectasia or breast edema, fibrosis
causing breast swelling and tenderness, depend on the dose,
the irradiated volume and the individual radiosensitivity [7–
10]. The overdosing of small volumes in the irradiated breast
(i.e. dose inhomogeneity), a phenomenon related to the
technique applied, favors breast fibrosis [11–15]. The impact
of the systemic therapy on the cosmetic outcome has been
the subject of numerous studies [11, 13, 15–17]. Adjuvant
chemotherapy [18] and tamoxifen therapy [6, 18] have been
suggested to predict a poor cosmetic outcome [17]. We set
out a retrospective cohort analysis to study the patient- and
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therapy related factors that may influence the cosmetic and
functional outcomes among our breast cancer patients after
breast-conserving surgery and conformal radiotherapy, with
or without adjuvant systemic therapy.
Materials and Methods
The clinical data on 198 breast cancer patients who
participated in postoperative radiotherapy were extracted
from a prospectively compiled database. The mean age of
the population was 62.0±10.6 (range 25–89) years. Eligible
patients had undergone unilateral breast-conserving surgery,
with or without sentinel lymph node biopsy or/and axillary
lymph node dissection and conformal radiotherapy 1–
5 years before the interview. Patients with prior malignancy
or any other significant health problem were excluded, as
were those on glucocorticoid therapy. The patients had been
operated between May 2004 and December 2008, at either
the Department of Surgery, University of Szeged, or at
smaller surgical departments.
Use of the following adjuvant medical therapies was
permitted: a taxane-based postoperative chemotherapy
regimen (involving either docetaxel or paclitaxel at con-
ventional doses) completed ≥4 weeks prior to the radio-
therapy (n=23, 13.1%); adjuvant hormone therapy with
either tamoxifen (20 mg/day) or an aromatase inhibitor
(anastrozole, 1 mg/day, or letrozole, 2.5 mg/day), started
≥2 weeks before the initiation of radiotherapy (n=49,
24.7% and n=48, 24.2%, respectively); patients who did
not received any systemic medication during or after the
radiotherapy were also eligible for enrolment (n=75,
37.9%). CT-based three-dimensional treatment planning
and conformal radiotherapy were performed in all cases
with the patient in a supine position. All relevant technical
details have been published previously [19]. Briefly, CT
images were acquired at 1 cm intervals throughout the
entire planning volume. The target volume and organs at
risk (OARs) were contoured on the CT slices in the
radiotherapy planning system. The planning target volume
(PTV) coverage was analyzed via the dose-volume histo-
grams and isodose visualization. Local or locoregional
radiotherapy was chosen according to the local protocol.
The tumor bed boost was delivered with either 6 MV
photon or 8–15 MeV electron fields. The radiation dose to
the remaining breast parenchyma/chest wall and to the
lymph nodes, if indicated, was 25x2 Gy (prescribed to the
mean of the PTV); a tumor bed boost of 5-8x2 Gy was
delivered when necessary. OAR constraints were used as
previously described [19].
The following radiotherapy-related data were extracted from
our database: the PTV, the volume of the PTV that received
more than 47.5 Gy, but less than 53.5 Gy (V95%–107%), the
overdosed volume of the PTV (V>107%), the volume and dose
of the tumor bed boost, the technique used and the breast
separation (BS), i.e. the distance between the points at which
the tangential fields entered the body.
The cosmetic outcome was evaluated at a single routine
6-month check-up visit, 1–5 years after the radiotherapy.
The patients were examined, and a questionnaire relating to
the following items was completed: the overall cosmetic
success in the opinions of the patient and the physician
(G. K. or Z. K.), the presence of breast fibrosis or
edema, teleangiectasia or dyspigmentation, all scored on
a 4-point categorical scale according to the modified
system of Johansen et al. [15, 18]. Briefly, the following
scoring system was used. Breast fibrosis: 0: none, 1:
density slightly increased, 2: increased density and
firmness, 3: very marked density with retraction; Edema:
0: none, 1: trace thickening of the skin, 2: marked edema,
leathery skin texture, 3: severe edema with papillary
formation; Teleangiectasia: 0: none, 1: <1 cm, 2: 1–
4 cm, 3: >4 cm; Dyspigmentation: 0: none, 1: mild, 2:
moderate, 3: severe. Physicians classified the cosmetic
result as excellent if no asymmetry or changes of the skin
or the breast contour occurred; in the case of slight,
moderate or severe manifestation of at least one of these
factors, the outcome was considered good, fair or poor,
respectively. The patients were asked whether they felt
pain or tenderness in the operated breast, and whether they
had experienced changes in their body image or in their
clothing habits. The length of the excision scar and the
difference (regarded as measurable when ≥1.0 cm) in the
jugulum-nipple distance (indicative of breast asymmetry)
were recorded. Data were additionally collected on
smoking habits, with the participants categorized as past
or present smokers or non-smokers.
The various patient- and radiotherapy-related charac-
teristics associated with the cosmetic and functional
outcomes were analyzed by the means of the chi-square
test, analysis of variance and logistic regression. The
Kappa test was applied to investigate the connection
between the opinions of the physicians and the patients
as concerns the cosmetic outcome. Binary univariate
logistic regression models were first utilized separately,
followed by the multivariate logistic regression model to
examine joint effects and interactions. Statistical analysis was
performed with SPSS 15.0 for Windows.
Results
A total of 198 patients were enrolled in the study. The mean
age of the population was 62.0±10.6 (range 25–89) years.
The median follow-up time was 2.4 (range 1.2–5.9) years.
Most of the tumors measured ≤2.0 cm and were lymph
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node-negative (Table 1). Data concerning the radiotherapy
are presented in Table 2. One hundred and sixty-seven
patients (84.3%) received only breast irradiation, while 31
patients (15.7%) both breast and regional lymph node
irradiation. Twenty patients (10.1%) were treated with
taxane-based chemotherapy before the radiotherapy. The
systemic therapy before the radiotherapy started with an
aromatase inhibitor or tamoxifen alone, in 49 (24.7%)
and 48 (24.2%) cases, respectively. Four (2.0%) and
two (1.0%) patients received a taxane-based chemotherapy
and an aromatase inhibitor or tamoxifen thereafter,
respectively. Seventy-five patients (37.9%) did not
participate in systemic therapy.
The patients and the physicians considered the cosmetic
outcome to be excellent or good in 76.3% and 47% of the
cases, respectively; a weak correlation was observed
between the opinions of the physicians and the patients
(Table 3). A large majority of the patients (n=160, 80.8%)
underwent their breast surgery at our institute, and 127
(84.1%) of them regarded the cosmetic outcome as
excellent or good more often than did those who were
operated on in smaller surgical departments (n=24/38,
63.2%) (p=0.05). In the view of the physicians, the
cosmetic outcome overall was less often excellent or good
as the tumor size increased: the mean±SD tumor size was
1.3±0.7 and 1.5±0.7 cm in the excellent and good vs. the
fair and poor outcome groups, respectively (p=0.015).
Among those patients who had an axillary block dissection,
the physician considered the cosmetic outcome excellent or
good in 29 cases (37.7%), and fair or poor in 48 cases
(62.3%, p=0.04). A significant relation or interaction was
not detected between these variables in the logistic
regression analysis. The incidence and severity of hyper-
pigmentation, fibrosis, edema and teleangiectasia are
presented in Table 4.
Thirty-one patients (19.7%) complained of pain in the
operated breast, while 81 (40.9%) reported tenderness.
Breast tenderness occurred significantly more often among
premenopausal women or patients ≤50 years old (both p<
0.05). The average age (±SD) of the patients who
complained or had no complaint of breast tenderness was
59.8±11.6 and 63.6±9.6 years, respectively (p<0.05).
Breast fibrosis and/or edema occurred in 67 (33.9%) and
23 (11.6%) patients, respectively. Skin hyperpigmentation,
Table 1 Patient and tumor characteristics in the overall study population and according to the systemic therapy
Patient and tumor characteristics All n (%) Systemic therapy n
Chemotherapy Tamoxifen Aromatase inhibitor Chemotherapy and
hormonal therapy
None
Menostatus
Premenopausal 48 (24.2) 12 22 0 4 10
Postmenopausal 150 (75.8) 8 26 49 2 65
Age
≤50 years 20 (10.1) 9 6 0 1 4
>50 years 178 (89.9) 11 42 49 5 71
Lymph node surgerya
Sentinel node biopsy only 111 (56.0) 6 28 29 3 45
Axillary block dissection 77 (38.9) 14 18 18 3 24
Tumor size
≤2.0 cm 164 (82.8) 12 41 41 3 67
>2.0 cm 34 (17.2) 8 8 7 3 8
Lymph node positivity
Lymph node-negative 155 (78.3) 8 38 38 1 70
Lymph node-positive 43 (21.7) 12 10 11 5 5
Tumor location
Upper quadrants 130 (65.6) 16 31 33 3 47
Central 34 (17.2) 1 7 11 1 14
Lower quadrants 34 (17.2) 3 10 5 2 14
Smoking habits
Never smoked 125 (63.1) 12 23 38 3 49
Current or previous smoker 73 (36.9) 8 25 11 3 26
a Ten patients did not participate in lymph node surgery because of their advanced age
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found in altogether 71 patients (35.9%) occurred in 59
(83.1%) of the patients >50 years old, and 12 (16.9%) of
the women ≤50 years old, respectively (p<0.05), and its
incidence decreased with the median time elapsed after
radiotherapy (2.1 and 2.5 years in the presence and the
absence of hyperpigmentation, respectively, p=0.02).
Teleangiectasia developed in 22 patients (11.1%).
The mean±SD tumor size was 1.6±0.7 cm if moderate
dyspigmentation occurred, and 1.3±0.7 cm in the other
cases (p<0.05). The average ±SD tumor size was 1.9±
1.4 cm if breast marked edema occurred, and 1.4±0.7 cm in
the other cases (p<0.05). Breast edema occurred in 15
(65.2%) and 8 (34.8%) among those patients who had
or did not have axillary lymph node dissection,
respectively (p=0.01). Breast edema was related to
dyspigmentation (p=0.003), fibrosis (p<0.001) and breast
asymmetry (p=0.032), whereas none of these abnormali-
ties were associated with teleangiectasia.
Thirty-three (16.7%) patients mentioned changes in
their clothing habits and 44 (22.3%) had experienced a
variation in their body image. Those patients who
noticed body image changes were younger than those
who did not (the mean±SD age was 57.6±10.1 vs. 63.3
±10.4 years, respectively, p<0.005). Eighty-six percent
of the postmenopausal, and 74% of the ≤50 years old
women needed to change their clothing habits (p<0.05),
while this measure was 8.9% and 1.3% according to
whether the patient received or did not receive systemic
therapy, respectively (p<0.005).
In most cases, the excisional scar was in the upper
quadrants (n=130, 65.7%). The mean±SD length of the
scar was 8.2±3.5 (range, 3.0–28.0) cm. An average (±SD)
breast asymmetry (n=159) of 2.7±1.9 (range, 1.0–15.0) cm
was found in 159 of the 194 evaluable patients (nipple
excision was performed in 4 patients). The average extent
(±SD) of breast asymmetry was 2.4±2.2 cm vs. 1.5±0.9 cm
when the tumor was located in the upper vs. the lower
quadrants, respectively (p=0.05), and 2.1±1.7 cm vs. 2.9±
2.9 cm when the tumor diameter was ≤2 cm vs. >2 cm,Ta
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Table 3 Overall cosmetic outcome in the study population as
assessed by the patient and the physician
Cosmetic outcome Excellent Good Fair Poor
Patient’s
opinion (%)
93 (47.0) 58 (29.3) 44 (22.2) 3 (1.5)
Physician’s
opinion (%)
32 (16.2) 61 (30.8) 68 (34.3) 37 (18.7)
Kappa 0.09 p<0.05
The patients’ subjective appreciation and the cosmetic result as
classified by the physician (the absence of any abnormality, or the
slight, moderate or severe manifestation of breast asymmetry or
changes of the skin or the breast contour) are indicated
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respectively (p<0.05). The length of the scar did not
influence any attribute of the cosmetic outcome.
More severe dyspigmentation and breast edema occurred
in patients with larger PTVs (p<0.001). The risk of more
severe dyspigmentation and breast edema increased by 18%
and 23%, respectively, for every 100 cm3 increase in
irradiated breast volume (OR=1.18, 95% CI: 1.07–1.31;
OR=1.23, 95% CI: 1.12–1.36). Breast edema was more
frequent with increasing BS (p<0.005), and was not related
to nodal irradiation. The incidence of breast fibrosis was
significantly higher with larger PTVs (mean±SD value of
PTV, patients with breast fibrosis: 1221.5±571.8 cm3 and
patients without fibrosis: 1058.7±416.9 cm3, p<0.05). The
risk of breast fibrosis increased by 7% for every 100 cm3
increase in irradiated breast volume (OR=1.07, 95% CI:
1.00–1.14). No association was found between any of
the attributes of cosmesis and the dose inhomogeneity
within the irradiated volume. The dose inhomogeneity
was related to the volume of the irradiated breast (p=
0.037). The risk of V>107%≥1% increased by 8% for every
100 cm3 increase in irradiated breast volume (OR=1.078,
95% CI: 1.003–1.158).
A higher boost volume favored breast fibrosis and
edema (p<0.005 and p<0.001, respectively). The risk of
breast edema and breast fibrosis increased by 21% and
12%, respectively, for every 10 cm3 increase in boost
volume (OR=1.21, 95% CI: 1.09–1.33 and OR=1.12,
95%, CI: 1.03–1.12). Breast edema and/or fibrosis was
more frequent among those patients who received a
photon boost than those who received electrons (breast
edema: 13/63 vs. 4/98, p=0.001 and breast fibrosis: 26/63
vs. 26/98, p=0.038). No association was found between
the administration of systemic therapy and cosmetic or
functional outcome.
One hundred and twenty-five (63.1%) patients had never
smoked, 49 (24.7%) had smoked previously and 24 patients
(12.1%) smoked during the radiotherapy. Skin dyspigmen-
tation and teleangiectasia developed significantly less often
among the patients who had never smoked (both p<0.05).
Discussion
We evaluated the cosmetic outcome 1–5 years after
breast-conserving surgery, postoperative radiotherapy
and systemic therapy. Primarily radiotherapy-related
factors such as the irradiated volume, the radiation dose
and the beam quality, but also the size of the tumor, the
age of the patient, the surgical intervention and the
smoking habits influenced the cosmesis. Our analysis
provided novel information on the association between
late radiation toxicity and the dose-volume attributes of
the radiotherapy. With the intent of broad analysis we
applied a comprehensive instrument [15, 18], quantitative
radiotherapy data, and considered systemic therapy.
More than three-quarters of the patients considered the
cosmetic outcome to be excellent or good, which is similar
to the observations by other groups [14, 15, 17]. In contrast,
in the opinion of the physicians, only about half of the
cases belonged in this category. One explanation of the
discrepancy might be the strict conditions used for the
evaluation of the cosmetic appearance. A further contribut-
ing factor could have been the relatively short follow-up
time in our study since the consideration of the radiation
side-effects by the patient may change in time [16].
The location and stage of the tumor clearly determine the
cosmetic outcome [12, 14, 15, 20–22]. In our study, breast
edema, fibrosis, teleangiectasia and dyspigmentation were
all related to the size of the tumor, and were interrelated.
Similarly as in the studies by Johansen et al. and Taylor et
al., we found that tumors located in the upper quadrants and
those with a larger diameter were predisposed to more
severe breast asymmetry [14, 15].
The available data are not completely unequivocal as
regards the relation between a young age and the cosmetic
and functional outcomes. Most studies report an improved
cosmetic outcome among younger women [14, 17, 23, 24]
though the opposite to has been suggested [15]. We did not
find any age-specific differences in the overall cosmetic
outcome. However, the different components of the
cosmetic and functional results did depend on the age of
the patient. The more frequent breast tenderness or pain
among ≤50 years old women might have been related to
hormonal effects, and the change in body image in this age
group could have been dependent on psychological or
mental factors. The higher incidence of dyspigmentation in
those over 50 years of age is probably due to the age-
dependent response to radiation, with an increased accu-
mulation of melanin and lipofuscin, the pigments related to
aging and oxidative stress [25]. It is well known that
Table 4 Incidence and severity
of radiogenic changes of the
skin, subcutaneous tissue and
breast parenchyma according to
the modified scoring system of
Johansen et al. [15, 18]
Score 0 (%) Score 1 (%) Score 2 (%) Score 3 (%)
Hyperpigmentation 127 (64.1) 56 (28.3) 11 (5.6) 4 (2.0)
Fibrosis 131 (66.1) 37 (18.7) 30 (15.2) 0 (0.0)
Edema 175 (88.4) 14 (7.1) 8 (4.0) 1 (0.5)
Teleangiectasia 176 (88.9) 3 (1.5) 6 (3) 13 (6.6)
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radiogenic side-effects are more frequent for larger breasts.
Nevertheless, to the best of our knowledge, this analysis is
the first to report cosmetic results after conformal breast
radiotherapy in relation to dose-volume data. Although
conformal radiotherapy was applied in the study by Lilla et
al., a detailed analysis of the radiotherapy-related data was
not reported [24]. In that and other studies, the associations
between the side-effects and the irradiated volume were
based on approximate data such as the size of the breast or
the bra cup [15, 18, 24, 26, 27] and the chest wall
separation [26]. Likewise, dose homogeneity in the entire
PTV was predicted after visualization of the dose distribu-
tion at the central axis [22, 26] or was related to the use or
avoidance of tissue compensators or wedges [14, 28, 29]. In
one of these studies, the dose homogeneity demonstrated a
parallel with the breast size [26], an effect confirmed by our
results. In our study, no association was detected between
the dose inhomogeneity and poorer cosmesis as a result of
restricting the overdosed volume (V>107%) to 1% of the
PTV, and the superposition of individually weighted 6 or 15
MV segmental fields to the tangential fields [19]. Our
finding that the photon boost was more often related to
breast edema and fibrosis is in accordance with the outcome
of the robust analysis by Murphy et al. [27]. We consider
that this phenomenon is a consequence of the larger volume
irradiated when 2 photon fields are applied as compared
with the use of one direct electron field. For the best
cosmetic result, the use of an electron boost is recom-
mended, or the IMRT technique may be utilized [30–32].
Systemic therapy has been found detrimental to the
cosmetic and functional outcome in many studies [13, 14,
18, 22, 27, 33]. Most investigated the effects of chemo-
therapy with CMF or an antracycline-containing regimen,
either concurrently or sequentially with radiotherapy [14,
15, 33]. In the study by Johansen et al., chemotherapy with
CMF or with tamoxifen was associated with a 5-fold
(CMF) or 10-fold (tamoxifen) higher risk of breast fibrosis,
respectively [15]. Taxane-based combinations have become
a routine option in adjuvant chemotherapy, but the effects
of sequentially applied taxane-based chemotherapy on
breast cosmesis have not yet been reported. We did not
detect adverse effects of such a regimen, though the number
of patients was low. The third-generation aromatase
inhibitors currently compromise the standard endocrine
therapy of postmenopausal women with hormone-
dependent breast cancer. However, tamoxifen is still
administered in premenopausal and selected postmenopausal
women. Azria et al. demonstrated in their primal work
that letrozole does not exert a detrimental effect on
early or late radiation skin toxicity [10]. In accordance
with these findings, aromatase inhibitor therapy in our
analysis did not have any effect on the studied parameters.
In contrast, the prospective study by Azria et al. revealed
that the concurrent administration of tamoxifen with
radiotherapy doubled the risk of subcutaneous fibrosis
[8]. Likewise, we found that concomitant tamoxifen
increased the risk of lung fibrosis (OR=2.442) [19]. Due
to the limitations of the analyses, other reports have not
provided a clear answer as to the effect of simultaneous
tamoxifen therapy with radiotherapy on the cosmetic outcome
[6, 12, 14, 18]. Our survey suggested that tamoxifen therapy
was related to the change in body image, but since no
specific radiogenic changes were detected, the frequent
weight gain associated with this medication may have played
a role in this outcome measure.
Conclusions
The cosmetic outcome after breast-conserving surgery is
primarily determined by the stage of the disease and the
consequences of radiotherapy. Despite the achievements
made regarding the effectiveness and side-effect profile of
modern radiotherapy, a careful estimate of its benefits
remains necessary in each case and determination of the
individual treatment strategy accordingly.
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